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europsychiatric  manifestations  in autoimmune
iseases
anifestac¸ões  neuropsiquiátricas  em  doenc¸as autoimunes
r
1
2
3
4europsychiatric manifestations in autoimmune diseases are
ften observed; they are associated with increased morbid-
ty and mortality and with a poorer quality of life. Although
heir classiﬁcation is carried out on a more  systematic basis
n systemic lupus erythematosus (SLE) when compared to
ther diseases – in part because of its prevalence and diagnos-
ic difﬁculties – their importance cannot be ignored in other
heumatic diseases.
When patients with autoimmune diseases present with
europsychiatric manifestations, we  emphasize the impor-
ance of the exclusion of comorbidities, infections and side
ffects related to medications. In SLE, only 40% of primary
anifestations are related to disease activity.1
The study by van Weelden et al.2 raises an important point:
he use of alcohol and illicit drugs in juvenile SLE. The use
f alcohol and illicit drugs is associated with neuropsychi-
tric manifestations, but according to population studies, it
an also promote the development of psychiatric disorders in
he absence of autoimmune diseases.3,4 In their study, van
eelden et al.2 observed a high frequency of alcohol use
mong adolescents with SLE (38%), but similar to matched
ontrols; but with a low risk for illegal substances and depend-
nce in JSLE patients.
In the study by Aikawa et al.,5 the authors observed a low
requency of hepatitis C in patients with JSLE versus controls
2.5% vs. 0%, p = 1.0). Hepatitis C must be routinely screened
n patients with autoimmune manifestations; this disease is
ssociated with neuropsychiatric manifestations.6
With regard to primary neuropsychiatric manifestations,
ostallat et al.,7 in their analysis of a large cohort of patients
ith SLE, observed a prevalence of 14 (1.2%) patients with
yelopathy. Myelopathy occurred independently of the asso-
iation with disease activity, and no patient was beneﬁted
ith a complete recovery. Deaths occurred in 3 (21%) patients
uring an episode of myelopathy, but these were due to com-
lications related to treatment.
5Infectious complications are often observed in SLE patients
and are associated with high mortality rates, particularly in
the early years of the disease. Disease activity and immuno-
suppression are important risk factors. The study by Simioni
et al.8 showed that low Vitamin D levels are associated with
leukopenia. Longitudinal studies with appropriate replace-
ment of vitamin D are needed in order to assess whether
adequate levels of vitamin D may help in the improvement
of leukopenia and in reducing infection in patients with SLE,
thus improving mortality.
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